PARP1 and breast carcinoma: The LUZERN study explored the combination of two drugs—niraparib, a PARP inhibitor, and aromatase inhibitors—to treat women with HR-positive/HER2-negative advanced breast cancer, particularly those with BRCA mutations or other DNA repair issues.